American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients.
Adam CukerEric K TsengRobby NieuwlaatPantep AngchaisuksiriClifton BlairKathryn DaneJennifer DavilaMaria T DeSanchoDavid DiuguidDaniel O GriffinSusan R KahnFrederikus Albertus KlokAlfred Ian LeeIgnacio NeumannAshok PaiMarc RighiniKristen M SanfilippoDeborah M SiegalMike SkaraDeirdra R TerrellKamshad TouriElie A AklImad Bou AklAntonio BognanniMary Ellene BoulosRomina Brignardello-PetersenRana CharideMatthew ChanKarin Lee DearnessAndrea J DarziPhilipp KolbLuis Enrique Colunga LozanoRazan MansourGian Paolo MorganoRami Z MorsiGiovanna Muti-SchünemannAtefeh NooriBinu A PhilipThomas PiggottYuan QiuYetiani RoldanFinn SchünemannAdrienne StevensKarla SoloWojtek WierciochReem A MustafaHolger J SchünemannPublished in: Blood advances (2021)
This recommendation was based on low certainty in the evidence, which underscores the need for additional high-quality, randomized, controlled trials comparing different intensities of anticoagulation in critically ill patients. Other key research priorities include better evidence regarding predictors of thrombosis and bleeding risk in critically ill patients with COVID-19 and the impact of nonanticoagulant therapies (eg, antiviral agents, corticosteroids) on thrombotic risk.